Preclinical data showed promise in both systemic sclerosis bleomycin-induced mouse models and in patient-derived skin fibroblasts treated with EYD-001. The Food and Drug Administration (FDA) has ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results